Clinical Review on the Management of Breast Cancer Visceral Crisis

Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10-15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative. As its clinical definition is an open topic with nebulous criteria and much...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2023-04, Vol.11 (4), p.1083
Main Authors: Benvenuti, Chiara, Gaudio, Mariangela, Jacobs, Flavia, Saltalamacchia, Giuseppe, De Sanctis, Rita, Torrisi, Rosalba, Santoro, Armando, Zambelli, Alberto
Format: Article
Language:English
Subjects:
advanced breast cancer
Breast cancer
Cancer therapies
Case reports
CDK4/6 inhibitors
Chemotherapy
Clinical trials
definition criteria
Drug dosages
Endocrine therapy
Epidermal growth factor
hormone receptor-positive
Medical laboratories
Medical prognosis
Metastasis
objective response
Palliative care
Patients
Physiological aspects
Response rates
Review
visceral crisis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10-15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative. As its clinical definition is an open topic with nebulous criteria and much room for subjective interpretation, it poses a challenge for daily clinical practice. International guidelines recommend combined chemotherapy as first-line treatment for patients with visceral crisis, but with modest results and a very poor prognosis. Visceral crisis has always been a common exclusion criterion in breast cancer trials, and the available evidence mainly comes from limited retrospective studies which are not sufficient to draw solid conclusions. The outstanding efficacy of innovative drugs, such as CDK4/6 inhibitors, questions the role of chemotherapy in this setting. In the lack of clinical reviews, we aim to critically discuss the management of visceral crisis, advocating future treatment perspectives for this challenging condition.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11041083